As of 2025, more than half of brand and nearly 70% of generic drugs distributed in the U.S. were manufactured overseas, with only 9% of active pharmaceutical ingredient (API) manufacturers located domestically. In response, the FDA PreCheck initiative launched to accelerate domestic site readiness and approvals, alongside an executive order aimed at restoring U.S. manufacturing capacity. 

Leading life sciences organizations have answered the call for manufacturing expansion, collectively pledging hundreds of billions of dollars in investment for this goal. These investments are reshaping demand for commissioning, qualification, and validation (CQV), as well as automation and digitally enabled production capabilities. 

At the same time, as manufacturing expands, supply chains are being optimized. The shift toward smart factories is an attempt to foster supply chain resilience and agility—and to prevent drug shortages through better oversight and quality assurance. 

According to the European Commission, root causes for drug shortages in EU/EEA countries from 2022-2023 included: 

• Manufacturing issues (50.6%) 
• Unexpected increased demand (16.7%) 
• Commercial reasons (11.2%) 
• Distribution issues (10.6%) 
• Others (6.9%) 
• Quality issues (2.6%) 
• Regulatory issues (1.3%) 

Research from the Healthcare Distribution Alliance highlights that concentrated sourcing and globalized production remain primary drivers of drug shortages (it’s important to note that the positives of a global supply chain persist as long as they’re balanced with effective risk mitigation and strategic international partnerships). As a result, life sciences organizations are adopting diversified sourcing, near‑ and right‑shoring strategies, and improved data transparency to reduce single‑point failures. 

Additionally, organizations are responding to tighter capital and timeline scrutiny by compressing the distance between development and launch through faster tech transfer, earlier manufacturing involvement, and parallel validation strategies—aligned with FDA efforts such as the Commissioner’s National Priority Voucher (CNPV) program to accelerate review timelines.

As clinical development becomes more complex and patient expectations evolve, organizations are rethinking how trials are designed, launched, and managed. 

Decentralized and hybrid trials are central drivers of this transformation. ClinicalTrials.gov hosts more than 330,000 registered studies and over 42,000 posted results, supported by increasingly automated validation and digitized quality‑control workflows. 

At the same time, the National Institute of Health supports 60+ federally funded Clinical and Translational Science Award (CTSA) hubs, many of which are actively advancing decentralized and hybrid trial models. With regulatory guidance now clearly supporting decentralized elements, sponsors are embracing remote visits, digital data capture, and local care delivery to improve patient access and enrollment.  

This shift is forcing a parallel investment in data integrity, cybersecurity, and inspection‑ready workflows, as trial execution becomes more distributed across geographies and technologies. 

Digital transformation is also reshaping technology transfer, particularly between academic research, clinical development, and manufacturing. Digital batch records, MES platforms, and connected data environments are enabling faster, more reliable tech transfer across sites. 

More than 300 federal laboratories currently participate in structured tech transfer programs, and over 200 drugs and vaccines have originated from Bayh‑Dole–enabled university commercialization efforts. 

In 2026, digital maturity is defined less by tools and more by integration. Organizations are investing in digital systems that support earlier collaboration between R&D, clinical, and manufacturing teams, enabling smoother handoffs, clearer data continuity, and faster movement from lab to market.  

Global delivery strategies are being reassessed as life sciences organizations respond to talent shortages, cost pressures, speed to delivery, and regulatory complexity. Rather than choosing between onshore and offshore models, leaders are adopting more flexible, risk‑aware approaches. 

Reshoring has gained momentum, particularly for critical manufacturing and quality functions. However, global coordination remains essential. In the EU, 75% of medicines are managed under the European Medicines Agency’s (EMA) Union List of Critical Medicines, rather than through national production mandates—highlighting the continued importance of cross‑border collaboration.  

Similarly, the Organization for Economic Cooperation and Development (OECD) emphasizes that long‑term resilience depends on multi‑country supply‑chain cooperation, not isolation. 

This has accelerated the move toward right‑shoring—placing work where it can be executed most effectively based on risk profile, regulatory exposure, and timeline sensitivity.  

Blended delivery models that combine regional oversight with globally distributed execution are allowing organizations to scale operations while maintaining consistency and control. In 2026, global delivery success is less about geography and more about governance, integration, and execution discipline. 

The patent cliff remains one of the most significant pressures, with the industry facing an estimated $236 billion in revenue exposure by 2030. This has fueled a surge in deal activity—by October 2025, approximately $70 billion in upfront consideration had already been announced across 17 pharma M&A transactions valued at $1 billion or more. 

Pricing pressure is intensifying alongside consolidation. Beginning in 2026, Medicare is authorized to negotiate prices for high‑expenditure, single‑source drugs, expanding to 60 negotiated products by 2030.  

Early market response has been uneven—nearly 90% of Part B drugs and 71% of Part D drugs increased prices following IRA enactment, while a smaller subset proactively reduced pricing to manage long‑term exposure. 

Trade policy is adding further complexity. The U.S. announced 100% tariffs on certain imported branded or patented pharmaceuticals, with exemptions allowed for manufacturers that are building U.S. facilities—further incentivizing onshore expansion while increasing near‑term planning uncertainty. In 2026, competitive advantage depends on navigating these pressures without slowing development or disrupting patient access. 

As of 2025, the FDA has authorized approximately 1,000 AI‑enabled medical devices, and in 2024, 18 personalized medicines accounted for 38% of all newly approved therapeutic molecular entities. Additionally, last year an AI‑discovered drug successfully completed a randomized Phase 2a trial, providing early proof that these approaches can translate into real clinical progress. 

Digital twins are emerging as one of the most impactful applications of AI. By simulating patient trajectories and disease progression in randomized trials, digital twins can improve trial efficiency and reduce reliance on traditional control arms. In pediatric and high‑risk populations, in‑silico trials have demonstrated the potential to shorten trial duration and reduce patient exposure to ineffective or unsafe therapies. 

One specific use case shows how researchers at the Weizmann Institute of Science built AI‑powered personal digital twins using data from over 13,000 participants in the Human Phenotype Project to predict disease risk and treatment response, highlighting how AI has improved life sciences research. 

Predictive modeling is also accelerating discovery and development timelines. AI‑driven models are being used to forecast disease risk, trial outcomes, and manufacturing constraints earlier in the lifecycle, helping teams allocate resources more effectively and reduce late‑stage failure.  

AI‑enabled workflows have also shown the ability to compress drug discovery timelines from roughly 5 years to 12–18 months, while reducing costs by up to 40%. These models rely on predictive analytics that combine historical, real‑time, and multi‑omic data to anticipate outcomes, optimize dosing, and reduce variability across patient populations. 

Proof of these benefits have already emerged—the large‑scale predictive system Delphi-2M was trained on medical records from 400,000 people and can now predict the likelihood and timing of more than 1,200 diseases, in some cases up to 20 years ahead.  

Continuous monitoring is another factor within this trend. Wearables, connected devices, and real‑world data streams enable an ongoing assessment of treatment performance beyond clinical trials. This shift allows therapies to be evaluated and refined over time, supporting more adaptive, patient‑centered care models. 

Together, these capabilities are moving personalized medicine from static intervention toward dynamic, data‑driven innovation.